Decoy Therapeutics Inc.

Decoy Therapeutics Inc. reported a significant increase in net loss for the three and six months ended June 30, 2026, reaching $(2.37) million and $(4.60) million, respectively. The company also disclosed substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations for the next year without additional capital. Despite a recent private placement raising $3.5 million in June 2026, the company's cash and stockholders' equity decreased from year-end 2025.

Decoy Therapeutics Inc. announced a Special Meeting of Stockholders on September 14, 2026, to vote on key corporate actions. These include approving the issuance of shares upon the exercise of Milestone Warrants from a recent private placement, which could bring in an additional $17.5 million, and reducing the number of authorized common shares. The Board of Directors unanimously recommends stockholders vote in favor of all proposals.

Decoy Therapeutics Inc. filed an S-1 registration statement for the resale of up to 3,766,500 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Pre-Funded, Milestone, and Placement Agent Warrants, which were issued in a private placement that closed on June 29, 2026, generating $3.5 million in upfront gross proceeds for the company. While the company will not receive proceeds from the resale, it could receive approximately $19.1 million if all warrants are exercised for cash, intended for working capital and general corporate purposes. Decoy Therapeutics is a pre-clinical stage biotechnology company facing substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into late 2026.

Decoy Therapeutics Inc. announced a private placement financing expected to generate approximately $3.5 million in initial gross proceeds. The financing includes the sale of 592,217 shares or pre-funded warrants at $5.91 per share, along with milestone-based Series A, B, and C warrants. If fully exercised upon achieving clinical milestones and stockholder approval, these warrants could provide up to an additional $17.5 million, bringing the total potential gross proceeds to $21 million. The company plans to use the net proceeds for general corporate purposes, including advancing its lead asset into clinical trials.

Decoy Therapeutics Inc. (DCOY) has filed an S-1 registration statement to allow for the resale of up to 808,000 shares of its common stock by C/M Capital Master Fund, LP. These shares are issuable under an equity line of credit (ELOC) agreement, through which Decoy Therapeutics may receive up to $5,000,000 in gross proceeds. A significant portion (50%) of these net proceeds will be used to redeem Series B Preferred Stock, with the balance allocated to working capital. The filing also provides background on the company's pre-clinical biotechnology focus, its recent merger and name change from Salarius Pharmaceuticals, and its status as a smaller reporting company that has recently resolved Nasdaq listing compliance issues.

Decoy Therapeutics Inc. has filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual Meeting of Stockholders, scheduled for July 14, 2026, to be held via live audio webcast. Key items on the agenda include the election of three Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Board of Directors recommends a vote in favor of all proposed items. Stockholders of record as of May 22, 2026, are eligible to vote.

Decoy Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held on July 14, 2026. Stockholders of record as of May 22, 2026, will be eligible to vote. Due to a change in the meeting date by more than 30 days, new deadlines for shareholder proposals and director nominations have been established, all set for May 29, 2026.

Decoy Therapeutics Inc. reported a net loss of $(2.22) million for Q1 2026, a significant increase from $(1.71) million in Q1 2025. The company's cash, cash equivalents, and restricted cash decreased to $7.82 million from $10.71 million at year-end 2025. Management expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and lack of product sales revenue, indicating a need for additional capital to fund operations. The company recently completed a merger with Legacy Decoy and effected two reverse stock splits.

Decoy Therapeutics Inc. filed an amendment to its 10-K to include Part III information, which was previously omitted. The filing details the completion of its merger with Legacy Decoy on November 12, 2025, and the subsequent legal name change from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc. on January 8, 2026. The company also reported two reverse stock splits and significant management changes, including the appointment of Frederick E. Pierce as CEO and Director, Barbara Hibner as CSO, and Peter Marschel as CBO, all effective November 12, 2025.